Abstract
In the proteomic and genomic era, lung cancer researchers are increasingly under challenge with traditional protein analyzing tools. High output, multiplexed analytical procedures are in demand for disclosing the post-translational modification, molecular interactions and signaling pathways of proteins precisely, specifically, dynamically and systematically, as well as for identifying novel proteins and their functions. This could be better realized by single-cell proteomic methods than conventional proteomic methods. Using single-cell proteomic tools including flow cytometry, mass cytometry, microfluidics and chip technologies, chemical cytometry, single-cell western blotting, the quantity and functions of proteins are analyzed simultaneously. Aside from deciphering disease mechanisms, single-cell proteomic techniques facilitate the identification and screening of biomarkers, molecular targets and promising compounds as well. This review summarized single-cell proteomic tools and their use in lung cancer.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30
Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA (2016) First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev 5:CD010383
Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM (2017) Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 14(9):549–561
Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A et al (2008) Dynamic proteomics of individual cancer cells in response to a drug. Science 322:1511–1516
Zimmer A, Amar-Farkash S, Danon T, Alon U (2017) Dynamic proteomics reveals bimodal protein dynamics of cancer cells in response to HSP90 inhibitor. BMC Syst Biol 11(1):33
Fujii K, Nakamura H, Nishimura T (2017) Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma. Expert Rev Proteomics 14(4):373–386
Birse CE, Lagier RJ, FitzHugh W, Pass HI, Rom WN, Edell ES et al (2015) Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clin Proteomics 12(1):18
Li L, Wei Y, To L, Zhu CQ, Tong J, Pham NA et al (2014) Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nat Commun 5:5469
Bharti A, Ma PC, Salgia R (2007) Biomarker discovery in lung cancer-promises and challenges of clinical proteomics. Mass Spectrom Rev 26(3):451–466
Ocak S, Chaurand P, Massion PP (2009) Mass spectrometry-based proteomic profiling of lung cancer. Proc Am Thorac Soc 6(2):159–170
Soo RA, Adjei AA (2017) Predicting clinical outcomes using proteomics in non-small cell lung cancer-the past, present, and future. J Thorac Oncol 12(4):602–606
Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC et al (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362:433–439
Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE et al (2010) Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5(12):e15003
Jung YJ, Katilius E, Ostroff RM, Kim Y, Seok M, Lee S, Jang S, Kim WS, Choi CM (2017) Development of a protein biomarker panel to detect non-small-cell lung cancer in Korea. Clin Lung Cancer 18(2):e99–e107
Codreanu SG, Hoeksema MD, Slebos RJC, Zimmerman LJ, Rahman SMJ, Li M, Chen SC, Chen H, Eisenberg R, Liebler DC, Massion PP (2017) Identification of proteomic features to distinguish benign pulmonary nodules from lung adenocarcinoma. J Proteome Res 16(9):3266–3276
Solanki HS, Advani J, Khan AA, Radhakrishnan A, Sahasrabuddhe NA, Pinto SM et al (2017) Chronic cigarette smoke mediated global changes in lung mucoepidermoid cells: a phosphoproteomic analysis. OMICS 21(8):474–487
López-Sánchez LM, Jurado-Gámez B, Feu-Collado N, Valverde A, Cañas A, Fernández-Rueda JL, Aranda E, Rodríguez-Ariza A (2017) Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. Am J Physiol Lung Cell Mol Physiol ajplung.00119.2017. https://doi.org/10.1152/ajplung.00119.2017. [Epub ahead of print]
Gocheva V, Naba A, Bhutkar A, Guardia T, Miller KM, Li CM, Dayton TL, Sanchez-Rivera FJ, Kim-Kiselak C, Jailkhani N, Winslow MM, Del Rosario A, Hynes RO, Jacks T (2017) Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc Natl Acad Sci U S A 114(28):E5625–E5634
Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T (2007) A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst 99:858–867
Taguchi F, Solomon B, Gregorc V, Rodr H, Gray R, Kasahara K et al (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 99:838–846
Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H et al (2009) Classification by mass spectrometry can accurately and reliably predict outcome in patients with nonsmall cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol 4(6):689–696
Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M et al (2014) Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol 15:713–721
Grossi F, Rijavec E, Genova C, Barletta G, Biello F, Maggioni C et al (2017) Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. Br J Cancer 116(1):36–43
Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR (2016) SWOG S0709: Randomized phase II trial of erlotinib versus erlotinib plus carboplatin/paclitaxel in patients with advanced non-small cell lung cancer and impaired performance status as selected by a serum proteomics assay. J Thorac Oncol 11(3):420–425
Paul D, Chanukuppa V, Reddy PJ, Taunk K, Adhav R, Srivastava S, Santra MK, Rapole S (2016) Global proteomic profiling identifies etoposide chemoresistance markers in non-small cell lung carcinoma. J Proteome 138:95–105
Rovithi M, Lind JS, Pham TV, Voortman J, Knol JC, Verheul HM, Smit EF, Jimenez CR (2016) Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer. Proteomics Clin Appl 10(7):743–749
Nyberg F, Ogiwara A, Harbron CG, Kawakami T, Nagasaka K, Takami S et al (2011) Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients. PLoS One 6(7):e22062
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O et al (2017) Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first-line platinum-based doublet chemotherapy stratified by VeriStrat good versus VeriStrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. J Thorac Oncol 12(4):752–762
Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S et al (2017) Evaluation of the VeriStrat serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer 109:101–108
Tan YH, Lee KH, Lin T, Sun YC, Hsieh-Li HM, Juan HF, Wang YC (2008) Cytotoxicity and proteomics analyses of OSU03013 in lung cancer. Clin Cancer Res 14(6):1823–1830
Li Y, Zhang B, Wang X, Yan H, Chen G, Zhang X (2011) Proteomic analysis of apoptosis induction in human lung cancer cells by recombinant MVL. Amino Acids 41(4):923–932
Labots M, Schütte LM, van der Mijn JC, Pham TV, Jiménez CR, Verheul HM (2014) Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies. Oncologist 19(10):1028–1039
Cheung CHY, Juan HF (2017) Quantitative proteomics in lung cancer. J Biomed Sci 24:37
Yang L, Tang C, Xu B, Wang W, Li J, Li X, Qin H, Gao H, He K, Song S, Liu X (2015) Classification of epidermal growth factor receptor gene mutation status using serum proteomic profiling predicts tumor response in patients with stage IIIB or IV non-small-cell lung cancer. PLoS One 10(6):e0128970
Heath JR, Ribas A, Mischel PS (2016) Single cell analytic tools for drug discovery and development. Nat Rev Drug Discov 15(3):204–216
Gavasso S, Gullaksen S, Skavland J, Gjertsen BT (2016) Single-cell proteomics: potential implications for cancer diagnostics. Expert Rev Mol Diagn 16(5):579–589
Lu Y, Yang L, Wei W, Shi Q (2017) Microchip-based single-cell functional proteomics for biomedical applications. Lab Chip 17(7):1250–1263
Wei W, Shin YS, Ma C, Wang J, Elitas M, Fan R, Heath JR (2013) Microchip platforms for multiplex single-cell functional proteomics with applications to immunology and cancer research. Genome Med 5(8):75
Beck TN, Chikwem AJ, Solanki NR, Golemis EA (2014) Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. Physiol Genomics 46(19):699–724
Marrugal Á, Ojeda L, Paz-Ares L, Molina-Pinelo S, Ferrer I (2016) Proteomic-based approaches for the study of cytokines in lung cancer. Dis Markers 2016:2138627
Herzenberg LA, Parks D, Sahaf B, Perez O, Roederer M, Herzenberg LA (2002) The history of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clin Chem 48:1819–1827
Lamoreaux L, Roederer M, Koup R (2006) Intracellular cytokine optimization and standard operating procedure. Nat Protoc 1:1507–1516
Leelatian N, Doxie DB, Greenplate AR, Mobley BC, Lehman JM, Sinnaeve J et al (2017) Single cell analysis of human tissues and solid tumors with mass cytometry. Cytometry B Clin Cytom 92(1):68–78
Lin CC, Huang WL, Su WP, Chen HH, Lai WW, Yan JJ, Su WC (2010) Single cell phospho-specific flow cytometry can detect dynamic changes of phospho-Stat1 level in lung cancer cells. Cytometry A 77(11):1008–1019
Skavland J, Jorgensen KM, Hadziavdic K, Hovland R, Jonassen I, Bruserud O, Gjertsen BT (2011) Specific cellular signal transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer J 1(2):e4
Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML (2008) Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14(4):335–343
Lu Y, Liang H, Yu T, Xie J, Chen S, Dong H, Sinko PJ, Lian S, Xu J, Wang J, Yu S, Shao J, Yuan B, Wang L, Jia L (2015) Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry. Cancer 121(17):3036–3045
Mesri M, Birse C, Heidbrink J, McKinnon K, Brand E, Bermingham CL, Feild B, Fitzhugh W, He T, Ruben S, Moore PA (2013) Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues. PLoS One 8(11):e78885
Diercks AH, Ozinsky A, Hansen CL, Spotts JM, Rodriguez DJ, Aderem A (2009) A microfluidic device for multiplexed protein detection in nano-liter volumes. Anal Biochem 386:30–35
Shrestha B, Vertes A (2009) In situ metabolic profiling of single cells by laser ablation electrospray ionization mass spectrometry. Anal Chem 81:8265–8271
Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, Pavlov S, Vorobiev S, Dick JE, Tanner SD (2009) Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 81(16):6813–6822
Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C et al (2017) Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica 102(8):1361–1367
Levine JH, Simonds EF, Bendall SC, Davis KL, Amir e-AD, Tadmor MD et al (2015) Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162(1):184–197
Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B (2014) Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods 11(4):417–422
Rahman AH, Lavin Y, Kobayashi S, Leader A, Merad M (2017) High-dimensional single cell mapping of cerium distribution in the lung immune microenvironment of an active smoker. Cytometry B Clin Cytom https://doi.org/10.1002/cyto.b.21545. [Epub ahead of print]
Brodie TM, Tosevski V (2017) High-dimensional single-cell analysis with mass cytometry. Curr Protoc Immunol 118:5.11.1–5.11.25
Schuffler PJ, Schapiro D, Giesen C, Wang HA, Bodenmiller B, Buhmann JM (2015) Automatic single cell segmentation on highly multiplexed tissue images. Cytometry A 87(10):936–942
Angelo M, Bendall SC, Finck R, Hale MB, Hitzman C, Borowsky AD, Levenson RM, Lowe JB, Liu SD, Zhao S et al (2014) Multiplexed ion beam imaging of human breast tumors. Nat Med 20:436–442
Rost S, Giltnane J, Bordeaux JM, Hitzman C, Koeppen H, Liu SD (2017 Aug) Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections. Lab Investig 97(8):992–1003
Roth C, Stückrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H (2012) Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS One 7(6):e38248
Sun J, Michael Masterman-Smith M, Graham NA (2010) A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Res 70(15):6128–6138
Huang L, Michael SA, Chen Y, Wu H (2017) Current advances in highly multiplexed antibody-based single-cell proteomic measurements. Chem Asian J 12(14):1680–1691
Khoo BL, Warkiani ME, Tan DS, Bhagat AA, Irwin D, Lau DP, Lim AS, Lim KH, Krisna SS, Lim WT, Yap YS, Lee SC, Soo RA, Han J, Lim CT (2014) Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. PLoS One 9(7):e99409
Fan B, Li X, Chen D, Peng H, Wang J, Chen J (2016) Development of microfluidic systems enabling high-throughput single-cell protein characterization. Sensors (Basel) 16(2):232
Yu J, Zhou J, Sutherland A, Wei W, Shin YS, Xue M, Heath JR (2014) Microfluidics-based single-cell functional proteomics for fundamental and applied biomedical applications. Annu Rev Anal Chem 7:275–295
Chen H, Lau MC, Wong MT, Newell EW, Poidinger M, Chen J (2016) Cytofkit: a bioconductor package for an integrated mass cytometry data analysis pipeline. PLoS Comput Biol 12(9):e1005112
Cohen D, Dickerson JA, Whitmore CD, Turner EH, Palcic MM, Hindsgaul O, Dovichi NJ (2008) Chemical cytometry: fluorescence-based single-cell analysis. Annu Rev Anal Chem 1:165–190
Xu F, Zhao H, Feng X, Chen L, Chen D, Zhang Y, Nan F, Liu J, Liu BF (2014) Single-cell chemical proteomics with an activity based probe: identification of low-copy membrane proteins on primary neurons. Angew Chem Int Ed Engl 53(26):6730–6733
Yan H, Zhang B, Wu H (2008) Chemical cytometry on microfluidic chips. Electrophoresis 29(9):1775–1786
Kleparnik K (2015) Recent advances in combination of capillary electrophoresis with mass spectrometry: methodology and theory. Electrophoresis 36(1):159–178
Mainz ER, Dobes NC, Allbritton NL (2015) Pronase E-based generation of fluorescent peptide fragments: tracking intracellular peptide fate in single cells. Anal Chem 87(15):7987–7995
Sun L, Zhu G, Yan X et al (2014) Capillary zone electrophoresis for analysis of complex proteomes using an electrokinetically pumped sheath flow nanospray interface. Proteomics 14(4–5):622–628
Jung HJ (2017) Chemical proteomic approaches targeting cancer stem cells: a review of current literature. Cancer Genomics Proteomics 14(5):315–327
Kang CC, Yamauchi KA, Vlassakis J, Sinkala E, Duncombe TA, Herr AE (2016) Single cell-resolution western blotting. Nat Protoc 11(8):1508–1530
Hughes AJ, Spelke DP, Xu Z, Kang CC, Schaffer DV, Herr AE (2014) Single-cell western blotting. Nat Methods 11(7):749–755
Streets AM, Huang Y (2014) Microfluidics for biological measurements with single-molecule resolution. Curr Opin Biotechnol 25:69–77
Spitzer MH, Nolan GP (2016) Mass cytometry: single cells, many features. Cell 165(4):780–791
Amann JM, Chaurand P, Gonzalez A, Mobley JA, Massion PP, Carbone DP, Caprioli RM (2006) Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Cancer Res 12:5142–5150
Hmmier A, O’Brien ME, Lynch V, Clynes M, Morgan R, Dowling P (2017) Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry. BBA Clin 7:97–104
Carvalho AS, Cuco CM, Lavareda C, Miguel F, Ventura M, Almeida S et al (2017) Bronchoalveolar lavage proteomics in patients with suspected lung cancer. Sci Rep 7:42190
Fahrmann JF, Grapov DD, Wanichthanarak K, DeFelice BC, Salemi MR, Rom WN, Gandara DR, Phinney BS, Fiehn O, Pass H, Miyamoto S (2017) Integrated metabolomics and proteomics highlight altered nicotinamide- and polyamine pathways in lung adenocarcinoma. Carcinogenesis. pii: bgw205. https://doi.org/10.1093/carcin/bgw205. [Epub ahead of print]
Shen Q, Cheng F, Song H, Lu W, Zhao J, An X, Liu M, Chen G, Zhao Z, Zhang J (2017) Proteome-scale investigation of protein allosteric regulation perturbed by somatic mutations in 7000 cancer genomes. Am J Hum Genet 100(1):5–20
Backes C, Ludwig N, Leidinger P, Huwer H, Tenzer S, Fehlmann T, Franke A, Meese E, Lenhof HP, Keller A (2016) Paired proteomics, transcriptomics and miRNomics in non-small cell lung cancers: known and novel signaling cascades. Oncotarget 7(44):71514–71525
Xue M, Wei W, Su Y, Kim J, Shin YS, Mai WX, Nathanson DA, Heath JR (2015) Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells. J Am Chem Soc 137(12):4066–4069
Wiwie C, Baumbach J, Röttger R (2015) Comparing the performance of biomedical clustering methods. Nat Methods 12:1033–1038
Weber LM, Robinson MD (2016) Comparison of clustering methods for high-dimensional single-cell flow and mass cytometry data. Cytometry A 89(12):1084–1096
Shi L, Zhu B, Xu M, Wang X (2017) Selection of AECOPD-specific immunomodulatory biomarkers by integrating genomics and proteomics with clinical informatics. Cell Biol Toxicol https://doi.org/10.1007/s10565-017-9405-x
Hwang M, Park HH, Choi H, Lee KY, Lee YJ, Koh SH (2017) Effects of aspirin and clopidogrel on neural stem cells. Cell Biol Toxicol https://doi.org/10.1007/s10565-017-9412-y
Chu MP, Kriangkum J, Venner CP, Sandhu I, Hewitt J, Belch AR, Pilarski LM (2017 Apr) Addressing heterogeneity of individual blood cancers: the need for single cell analysis. Cell Biol Toxicol 33(2):83–97. https://doi.org/10.1007/s10565-016-9367-4
Wang W, Zhu B, Wang X (2017 Oct) Dynamic phenotypes: illustrating a single-cell odyssey. Cell Biol Toxicol 33(5):423–427. https://doi.org/10.1007/s10565-017-9400-2
Chen C, Shi L, Li Y, Wang X, Yang S (2016 Jun) Disease-specific dynamic biomarkers selected by integrating inflammatory mediators with clinical informatics in ARDS patients with severe pneumonia. Cell Biol Toxicol 32(3):169–184. https://doi.org/10.1007/s10565-016-9322-4
Gu J, Wang X (2016 Feb) New future of cell biology and toxicology: thinking deeper. Cell Biol Toxicol 32(1):1–3. https://doi.org/10.1007/s10565-016-9313-5.94
Amodio G, Sasso E, D’Ambrosio C, Scaloni A, Moltedo O, Franceschelli S, Zambrano N, Remondelli P (2016 Aug) Identification of a microRNA (miR-663a) induced by ER stress and its target gene PLOD3 by a combined microRNome and proteome approach. Cell Biol Toxicol 32(4):285–303. https://doi.org/10.1007/s10565-016-9335-z
Wang X (2016 Oct) New biomarkers and therapeutics can be discovered during COPD-lung cancer transition. Cell Biol Toxicol 32(5):359–361. https://doi.org/10.1007/s10565-016-9350-0
Zhu D, Liu Z, Pan Z, Qian M, Wang L, Zhu T, Xue Y, Wu D (2016 Aug) A new method for classifying different phenotypes of kidney transplantation. Cell Biol Toxicol 32(4):323–332. https://doi.org/10.1007/s10565-016-9337-x
Xu M, Wang X (2017 Aug) Critical roles of mucin-1 in sensitivity of lung cancer cells to tumor necrosis factor-alpha and dexamethasone. Cell Biol Toxicol 33(4):361–371. https://doi.org/10.1007/s10565-017-9393-x
Wang W, Gao D, Wang X (2017) Can single-cell RNA sequencing crack the mystery of cells? Cell Biol Toxicol https://doi.org/10.1007/s10565-017-9404-y. [Epub ahead of print]
Wang X (2016 Aug) CBT profiles of cabozantinib approved for advanced renal cell carcinomas. Cell Biol Toxicol 32(4):259–261. https://doi.org/10.1007/s10565-016-9349-6
Bao L, Zhang Y, Wang J, Wang H, Dong N, Su X, Xu M, Wang X (2016 Oct) Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer. Cell Biol Toxicol 32(5):419–435. https://doi.org/10.1007/s10565-016-9343-z
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Wang, Z., Zhang, X. (2018). Single Cell Proteomics for Molecular Targets in Lung Cancer: High-Dimensional Data Acquisition and Analysis. In: Gu, J., Wang, X. (eds) Single Cell Biomedicine. Advances in Experimental Medicine and Biology, vol 1068. Springer, Singapore. https://doi.org/10.1007/978-981-13-0502-3_7
Download citation
DOI: https://doi.org/10.1007/978-981-13-0502-3_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-0501-6
Online ISBN: 978-981-13-0502-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)